PharmAthene announces new non-clinical data confirm SparVax anthrax vaccine can provide protection against lethal anthrax challenge (PIP) 2.04 : Co announced that new non-clinical animal data from the co's SparVax next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Co. The data presented showed that immunization with SparVax provides dose-dependent protection against lethal anthrax infection. In the current study, New Zealand White rabbits were administered escalating doses of SparVax ranging from 0.003 micrograms to 1.0 micrograms of rPA. Control animals received either no immunization or were administered saline. Following immunization, the animals were challenged with B. anthracis spores (Ames strain). The results demonstrated that SparVax was effective in providing protection against lethal inhalation anthrax challenge and resulted in no adverse clinical observations. In the study, immunization with SparVax stimulated a dose-dependent antibody response, which correlated with
The co also provided an update about the proposed merger. On Sep 9, 2013, PharmAthene filed a registration statement on Form S-4 with the SEC, which contains a preliminary proxy statement/prospectus/consent solicitation and other relevant materials, and plans to file with the SEC other documents regarding the proposed transaction. Once the registration statement has been declared effective, the final joint proxy statement / prospectus / consent solicitation will be sent to the stockholders of PharmAthene and Theraclone in connection with the stockholder votes on matters relating to the proposed transaction.